THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Wednesday, December 27, 2023
Biopharmaceuticals can become the backbone of the pharmaceutical industry only with significant laboratory, strategy, technology, and operations transformations.
FREMONT, CA: Biopharmaceuticals are among the twenty-first century's most sophisticated and exquisite scientific achievements. Not only do the enormous, intricate structures of these medications appear extraordinary in the 3-D modeling systems used to design them, but they also perform their tasks extraordinarily well, with high efficacy and few side effects. Existing treatment archetypes constantly evolve and become more complex, and ongoing research yields new product types. Cell therapy is leveraged by professionals to treat cancer, and, somewhat further in the future, gene therapies, which offer even more great promises of regenerative medicine or disease remission, are entering the market.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
There are problems with technology and how things work. To successfully make large molecules at an industrial scale requires a manufacturing sophistication that has never been seen before. A therapeutic molecule can have anywhere from 2,000 to 25,000 atoms. The "machines" that make recombinant therapeutics are genetically modified live cells that must be frozen to store, thawed without getting hurt, and grown in the strange environment of a reaction vessel. The molecules must then be removed from the cells that made them and the medium in which they were made without breaking their delicate, complex structures.
The opportunity in biopharmaceuticals needs to be bigger and expanding too quickly to be ignored. Biopharmaceuticals generate $163 billion in global revenue, constituting approximately 20 percent of the pharmaceutical market. Biopharma's current annual growth rate is double that of conventional pharma, and growth will continue at this rate for the foreseeable future. Due to the efficacy, safety, and ability to treat previously untreatable conditions of biopharmaceutical products, pharmaceutical companies can command high prices for innovative medications. The high cost of products sold and strong demand has led to substantial profits.
Biopharmaceuticals have established new benchmarks for blockbuster medicines. For many participants, producing enough products to sell is the greatest obstacle. The R&D and sourcing priorities of the world's largest pharmaceutical companies are progressively shifting towards large-molecule products. Investing in biotech R&D has produced higher returns than the average for the pharmaceutical industry for clinical trials. The success of the clinical pipeline will result in an unprecedented number of new molecules, rising annually in the future, as biopharmaceutical products constitute an increasing proportion of new FDA approvals.
The current pipeline for the development of biologics suggests sustained growth. Multiple companies receive approval for the production of biosimilars, resulting in a sharp rise in demand. Innovations such as immunotherapies, antibody-drug conjugates, and gene and cell therapies are progressing toward commercialization. Biopharma appears poised to transform the industry once more, as a better understanding of how medications interact with patients' genetic makeup improves the targeting of therapies. With robust, low-cost genetic profiling, this information will enhance treatment outcomes, accelerate and improve clinical trial outcomes, and help reduce the cost of drug development.
As the biopharmaceutical industry transitions from the scientific frontier to the business mainstream, it will increasingly face the same challenges as other industries of maintaining competitiveness by assuring affordability, quality, and delivery performance. These constraints will inevitably lead to the development of the biosimilars industry. The availability of biosimilar versions of human growth hormones and interferons has significantly expanded patient access to these medications. Biopharma operations and supply chain complexity will increase as the number of products increases and new process technologies are implemented.
More in News